Acute myeloid leukemia: conventional cytogenetics, FISH, and moleculocentric methodologies.

Acute myeloid leukemia (AML) is a complex group of hematologic neoplasms characterized by distinctive morphologic, immunophenotypic, and genetic abnormalities. However, it has become evident that genetic aberrations are central to the genesis of AML and have assumed an increasingly relevant role in the classification of AML. Here we discuss hallmark recurrent translocations that define specific World Health Organization (WHO) entities and other frequently encountered genetic aberrations that do not (yet) define specific entities. Additionally, we discuss emerging technologies and their application to the discovery of new abnormalities and to their potential role in the future diagnosis and classification of AML.

[1]  S. Raimondi,et al.  Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. , 2009, Blood.

[2]  George A Calin,et al.  MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. , 2008, Blood.

[3]  A. Hagemeijer,et al.  Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  K. Akashi,et al.  Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. , 1996, Blood.

[5]  C. O'keefe,et al.  Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. , 2008, Blood.

[6]  F. Sigaux,et al.  Prognostic significance of chromosomal abnormalities in acute nonlymphocytic leukemia: a study of 343 patients. , 1987, Cancer genetics and cytogenetics.

[7]  Torsten Haferlach,et al.  Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Joshua F. McMichael,et al.  DNMT3A mutations in acute myeloid leukemia. , 2010, The New England journal of medicine.

[9]  Kerby Shedden,et al.  Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia. , 2010, Blood.

[10]  A. Goldfarb,et al.  Oncogenic pathways of AML1-ETO in acute myeloid leukemia: multifaceted manipulation of marrow maturation. , 2007, Cancer letters.

[11]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[12]  C. Marosi,et al.  Prognostic impact of karyotype and immunologic phenotype in 125 adult patients with de novo AML. , 1992, Cancer genetics and cytogenetics.

[13]  G. Wertheim,et al.  Nucleophosmin (NPM1) mutations in acute myeloid leukemia: an ongoing (cytoplasmic) tale of dueling mutations and duality of molecular genetic testing methodologies. , 2008, The Journal of molecular diagnostics : JMD.

[14]  B. Löwenberg,et al.  Acute myeloid leukemia with monosomal karyotype at the far end of the unfavorable prognostic spectrum , 2011, Haematologica.

[15]  J. Reilly.  Pathogenesis of acute myeloid leukaemia and inv(16)(p13;q22): a paradigm for understanding leukaemogenesis? , 2005, British journal of haematology.

[16]  A. Bagg,et al.  Molecular diagnosis of acute myeloid leukemia , 2010, Expert review of molecular diagnostics.

[17]  Ulrich Mansmann,et al.  An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. , 2008, Blood.

[18]  N. Majhail,et al.  Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review. , 2010, Leukemia research.

[19]  A. Bagg,et al.  A comparative analysis of molecular genetic and conventional cytogenetic detection of diagnostically important translocations in more than 400 cases of acute leukemia, highlighting the frequency of false-negative conventional cytogenetics. , 2011, American journal of clinical pathology.

[20]  Tom H. Pringle,et al.  The human genome browser at UCSC. , 2002, Genome research.

[21]  Ming Yan,et al.  Persistent altered fusion transcript splicing identifies RUNX1‐RUNX1T1+ AML patients likely to relapse , 2010, European journal of haematology.

[22]  M. Caligiuri,et al.  Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. , 1996, Blood.

[23]  G. Marit,et al.  Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. , 1995, Leukemia.

[24]  G. Ehninger,et al.  Analysis of Flt3-activating Mutations in 979 Patients with Acute Myelogenous Leukemia: Association with Fab Subtypes and Identification of Subgroups with Poor Prognosis , 2022 .

[25]  M. McDevitt,et al.  New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  C. Bloomfield,et al.  Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  T. Golan,et al.  Predictive value of TP53 fluorescence in situ hybridization in cytogenetic subgroups of acute myeloid leukemia , 2011, Leukemia & lymphoma.

[28]  A. Kohlmann,et al.  AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features , 2009, Leukemia.

[29]  H. Dombret,et al.  Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML) , 2006, Leukemia.

[30]  F. Behm,et al.  Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. , 1999, Blood.

[31]  T. Lister,et al.  Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia. , 2008, Blood.

[32]  K. Döhner,et al.  Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  H. Kantarjian,et al.  Acute myeloid leukemia with t(9;11)(p21-22;q23): common properties of dysregulated ras pathway signaling and genomic progression characterize de novo and therapy-related cases. , 2010, American journal of clinical pathology.

[34]  E. Volpi,et al.  FISH glossary: an overview of the fluorescence in situ hybridization technique. , 2008, BioTechniques.

[35]  A. Hirt,et al.  The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukaemia. A study of the Swiss Paediatric Oncology Group (SPOG) , 2007, European journal of haematology.

[36]  C. Pui,et al.  Biology, risk stratification, and therapy of pediatric acute leukemias: an update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  I. Bernstein,et al.  Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. , 2010, Blood.

[38]  R. Larson,et al.  Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. , 2010, Chemico-biological interactions.

[39]  Guido Marcucci,et al.  The prognostic and functional role of microRNAs in acute myeloid leukemia. , 2011, Blood.

[40]  R. Beuscart,et al.  Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases , 1989, British journal of haematology.

[41]  A. Cherry,et al.  Utility of interphase FISH to stratify patients into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) clinical trial (E1900). , 2007, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

[42]  W. Hiddemann,et al.  AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. , 2003, Blood.

[43]  F. Appelbaum,et al.  Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. , 2010, Blood.

[44]  T. Meitinger,et al.  Identification of recurring tumor-specific somatic mutations in acute myeloid leukemia by transcriptome sequencing , 2011, Leukemia.

[45]  K Holzmann,et al.  Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis , 2010, Leukemia.

[46]  C. Bloomfield,et al.  A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare ‘poor prognosis’ myeloid malignancies , 2006, Leukemia.

[47]  P. Paschka.  Core binding factor acute myeloid leukemia. , 2008, Seminars in oncology.

[48]  E. van den Berg,et al.  Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  N. Bolli,et al.  Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? , 2011, Blood.

[50]  S. Fröhling,et al.  Diagnostic value of fluorescence in situ hybridization for the detection of genomic aberrations in older patients with acute myeloid leukemia. , 2005, Haematologica.

[51]  I. Bar-Am,et al.  Classical and molecular cytogenetic abnormalities and outcome of childhood acute myeloid leukaemia: report from a referral centre in Israel , 2004, British journal of haematology.

[52]  Stefan Fröhling,et al.  Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. , 2005, Blood.

[53]  Yoshiaki Ito,et al.  Molecular basis for a dominant inactivation of RUNX1/AML1 by the leukemogenic inversion 16 chimera. , 2004, Blood.

[54]  D. Gilliland,et al.  Core-binding factors in haematopoiesis and leukaemia , 2002, Nature Reviews Cancer.

[55]  Paola Fazi,et al.  Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). , 2010, Blood.

[56]  Guido Marcucci,et al.  Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. , 2006, Blood.

[57]  Groupe Français de Cytogénétique Hématologique.  Acute myelogenous leukemia with an 8;21 translocation. A report on 148 cases from the Groupe Français de Cytogénétique Hématologique. , 1990, Cancer genetics and cytogenetics.

[58]  K. Döhner,et al.  Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  Lynne V Abruzzo,et al.  Acute myeloid leukemia associated with variant t(8;21) detected by conventional cytogenetic and molecular studies: a report of four cases and review of the literature. , 2006, American journal of clinical pathology.

[60]  B. Ebert.  Genetic deletions in AML and MDS. , 2010, Best practice & research. Clinical haematology.

[61]  Ana-Teresa Maia,et al.  In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. , 2002, Blood.

[62]  E. Green,et al.  Isolation and analysis of candidate myeloid tumor suppressor genes from a commonly deleted segment of 7q22. , 2005, Genomics.

[63]  J. Reilly,et al.  Incidence and prognosis of c‐KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias , 2003, British journal of haematology.

[64]  R. Berger,et al.  Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Français de Cytogénétique Hématologique (GFCH). , 2002, Blood.

[65]  Emily H Turner,et al.  Targeted Capture and Massively Parallel Sequencing of Twelve Human Exomes , 2009, Nature.

[66]  E. Gehan,et al.  Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. , 1988, Leukemia.

[67]  Claudio Lottaz,et al.  Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia , 2007 .

[68]  K. Wagner,et al.  Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. , 2011, Blood.

[69]  L. Medeiros,et al.  Therapy-related acute myeloid leukemia with t(8;21) (q22;q22) shares many features with de novo acute myeloid leukemia with t(8;21)(q22;q22) but does not have a favorable outcome. , 2009, American journal of clinical pathology.

[70]  R. Hills,et al.  Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. , 2005, Blood.

[71]  Amy E. Hawkins,et al.  DNA sequencing of a cytogenetically normal acute myeloid leukemia genome , 2008, Nature.

[72]  R. Hills,et al.  Independent prognostic variables in acute myeloid leukaemia. , 2011, Blood reviews.

[73]  Erdogan Taskesen,et al.  Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. , 2011, Blood.

[74]  Ryan D. Morin,et al.  Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype , 2010, Nature Medicine.

[75]  J. Bennett,et al.  B-Lymphoblastic Leukemia/Lymphoma , 2014 .

[76]  J. Rowley,et al.  Leukaemogenesis: more than mutant genes , 2010, Nature Reviews Cancer.

[77]  T. Haferlach,et al.  Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. , 2009, Blood.

[78]  F. E. Bertrand,et al.  The MLL partial tandem duplication in acute myeloid leukaemia , 2006, British journal of haematology.

[79]  R. Larson,et al.  Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo. , 1988, Leukemia.

[80]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[81]  O. Haas,et al.  Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  Yong-mei Zhu,et al.  Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia , 2011, Nature Genetics.

[83]  W. Hiddemann,et al.  1 KIT-D 816 mutations in AML 1-ETO positive AML are associated with impaired event-free and overall survival , 2005 .

[84]  N. Zeleznik-Le,et al.  Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites. , 1996, Blood.